The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. (2019)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/blood.2019001861
PubMed Identifier: 31578205
Publication URI: http://europepmc.org/abstract/MED/31578205
Type: Journal Article/Review
Volume: 134
Parent Publication: Blood
Issue: 23
ISSN: 0006-4971